Compare Marathon Petroleum Corp (MPC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs TransMedics Group Inc — how do they compare? Marathon Petroleum Corp trades at $318.36 (market cap $92.05B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Marathon Petroleum Corp is far larger — about 36.2× TransMedics Group Inc's market cap, and Marathon Petroleum Corp pays a 1.24% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MPC | TMDX | |
|---|---|---|
Market Cap | $92.05B | $2.54B |
Sector | Energy | Technology |
52-Week High | $315.31 | $150.42 |
52-Week Low | $158.59 | $61.99 |
Enterprise Value | $124.23B | $2.94B |
Dividend Yield | 1.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
